| Symbol | AEMD |
|---|---|
| Name | AETHLON MEDICAL INC |
| Sector | HEALTH CARE |
| Region | UNDEFINED |
| Industry | Surgical & Medical Instruments & Apparatus |
| Address | 11555 SORRENTO VALLEY ROAD, SUITE 203, SAN DIEGO, CA 92121 |
| Telephone | 619-941-0360 |
| Fax | — |
| — | |
| Website | https://www.aethlonmedical.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Aethlon Medical Inc is a medical technology company. It is focused on addressing unmet needs in health and biodefense. The company operates through two segments namely Aethlon for therapeutic applications, which represents its therapeutic business activities and ESI for diagnostic applications which signifies diagnostic business activities. It is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and to eliminate life-threatening viruses from the circulatory system. The company generates revenue from Aethlon segment. Additional info from NASDAQ: |
Director Rossetti Angela 🟢 acquired 21.8K shares of AETHLON MEDICAL INC (AEMD) at $2.29 Transaction Date: Apr 17, 2026 | Filing ID: 003114
Read moreDirector Shah Chetan 🟢 acquired 21.8K shares of AETHLON MEDICAL INC (AEMD) at $2.29 Transaction Date: Apr 17, 2026 | Filing ID: 003113
Read moreDirector BROENNIMAN EDWARD G 🟢 acquired 21.8K shares of AETHLON MEDICAL INC (AEMD) at $2.29 Transaction Date: Apr 17, 2026 | Filing ID: 003111
Read moreDirector Gikakis Nicolas 🟢 acquired 21.8K shares of AETHLON MEDICAL INC (AEMD) at $2.29 Transaction Date: Apr 17, 2026 | Filing ID: 003112
Read moreDirector Shah Chetan 🔴 sold 178 shares of AETHLON MEDICAL INC (AEMD) at $2.19 Transaction Date: Mar 31, 2026 | Filing ID: 002589
Read moreDirector Gikakis Nicolas 🔴 sold 178 shares of AETHLON MEDICAL INC (AEMD) at $2.19 Transaction Date: Mar 31, 2026 | Filing ID: 002588
Read moreDirector BROENNIMAN EDWARD G 🔴 sold 89 shares of AETHLON MEDICAL INC (AEMD) at $2.19 Transaction Date: Mar 31, 2026 | Filing ID: 002587
Read moreAethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review
Read moreAethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT04595903 | Treatment of SARS-CoV-2 Virus Disease (COVID-19) in Humans With Hemopurifier® D… | Na | COVID-19 | Terminated | 2022-06-01 | 2022-11-14 | ClinicalTrials.gov |
| NCT04453046 | Hemopurifier Plus Pembrolizumab in Head and Neck Cancer | Na | Squamous Cell Carcinoma of the Head and Neck | Terminated | 2020-10-22 | 2022-11-14 | ClinicalTrials.gov |
| NCT02215902 | Safety Study of the Aethlon Hemopurifier | Na | End Stage Renal Disease | Terminated | 2014-12-01 | 2017-03-10 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Pembrolizumab 200mg IV | DRUG | Approved | Squamous Cell Carcinoma of the Head and Neck | TERMINATED | NCT04453046 |
| Hemopurifier | DEVICE | Approved | COVID-19 | TERMINATED | NCT04595903 |
| Affinity plasmapheresis | DEVICE | Approved | End Stage Renal Disease | TERMINATED | NCT02215902 |